Why The U.K. Is Shaping Up As A Prominent Vaccine Manufacturing Hub?

Highlights

• AstraZeneca invests USD 827 million to ramp up vaccine manufacturing in the U.K.

• The investment will strengthen the country’s pandemic readiness

• The biopharmaceutical firm will set up a new facility at Speke, Liverpool and enhance current infrastructure at Cambridge

Biopharmaceutical company AstraZeneca will invest about USD 827 million in the U.K. to give a push to the country’s vaccine manufacturing sector.

AstraZeneca plans to split the investment with approximately USD 573 million being allocated to setting up research and manufacturing facilities at its Speke, Liverpool site. The new campus will focus on manufacturing vaccines for AstraZeneca’s child immunisation program. The establishment will be powered by renewable energy, functioning as a net zero plant.

The biopharmaceutical company will also collaborate with the U.K. Health Security Agency (HSA) to strengthen resilience against future outbreaks of diseases. Under the agreement with the U.K. government, the Speke site will coordinate with HSA’s Vaccine Development Evaluation Centre.

The remaining USD 254 million will be used to expand the company’s existing facilities at its global headquarters in Cambridge. The upcoming project includes erecting an additional site as part of the company’s life sciences cluster. The establishment will be located along side AstraZeneca’s research and development discovery centre with a workforce totaling 1,000.

Pascal Soriot, CEO of AstraZeneca, said that the capital infusion would boost the U.K.’s readiness to deal with future pandemics while building the country’s status as a life sciences hub.

The investment marks a change in AstraZeneca’s plans after the company considered setting up a new manufacturing plant in Ireland amid doubts over Britain’s business climate.

Among other developments, AstraZeneca will unveil a new plant in Macclesfield to manufacture medication, to be used as part of a cancer treatment plan. The biopharmaceutical firm had put in USD 484 million in 2021 to build the facility. The plant is scheduled to open later in 2024.

The U.K. was the first country to give the green signal to the coronavirus vaccine manufactured in collaboration between AstraZeneca and Oxford University.

AstraZeneca’s investments also cover the U.S. healthcare industry. The firm had allocated USD 300 million to set up a cell therapy unit in Rockville, Maryland. The facility will support cancer trials with an eye on future commercial production.